Cytochrome P450 loss-of-function polymorphism genotyping on the Agilent Bioanalyzer and clinical application
Published 2009 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Cytochrome P450 loss-of-function polymorphism genotyping on the Agilent Bioanalyzer and clinical application
Authors
Keywords
-
Journal
PHARMACOGENOMICS
Volume 10, Issue 12, Pages 1987-1994
Publisher
Future Medicine Ltd
Online
2009-12-03
DOI
10.2217/pgs.09.127
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- The CYP2D6*4 polymorphism affects breast cancer survival in tamoxifen users
- (2009) Monique J. Bijl et al. BREAST CANCER RESEARCH AND TREATMENT
- Relative Impact of Genotype and Enzyme Induction on the Metabolic Capacity of CYP2C9 in Healthy Volunteers
- (2009) SV Vormfelde et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Effects of the CYP2D6*10 alleles and co-medication with CYP2D6-dependent drugs on risperidone metabolism in patients with schizophrenia
- (2009) Tatsuhiko Yagihashi et al. HUMAN PSYCHOPHARMACOLOGY-CLINICAL AND EXPERIMENTAL
- Cytochrome P450 2C19 polymorphism and clopidogrel after MI
- (2009) Sanjeev Bhattacharyya et al. LANCET
- CYP2D6 Genotype Predicts Antipsychotic Side Effects in Schizophrenia Inpatients: A Retrospective Matched Case-Control Study
- (2009) Camilla J. Kobylecki et al. NEUROPSYCHOBIOLOGY
- Estimation of the Warfarin Dose with Clinical and Pharmacogenetic Data
- (2009) NEW ENGLAND JOURNAL OF MEDICINE
- Evaluation of risk factors for elevated tricyclic antidepressant plasma concentrations
- (2009) Sarah J. Billups et al. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY
- Pharmacogenetic variation at CYP2C9, CYP2C19, and CYP2D6 at global and microgeographic scales
- (2009) Johanna Sistonen et al. Pharmacogenetics and Genomics
- A Genome-Wide Association Study Confirms VKORC1, CYP2C9, and CYP4F2 as Principal Genetic Determinants of Warfarin Dose
- (2009) Fumihiko Takeuchi et al. PLoS Genetics
- Association between CYP2D6 *10 genotype and survival of breast cancer patients receiving tamoxifen treatment
- (2008) Y. Xu et al. ANNALS OF ONCOLOGY
- Genetic Variation in the CYP2D6 Gene Is Associated With a Lower Heart Rate and Blood Pressure in β-Blocker Users
- (2008) MJ Bijl et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Pharmacogenetic Testing in Psychiatry: A Review of Features and Clinical Realities
- (2008) José de Leon et al. CLINICS IN LABORATORY MEDICINE
- Pharmacogenomics and Personalized Use of Drugs
- (2008) Jing-Fang Wang et al. CURRENT TOPICS IN MEDICINAL CHEMISTRY
- The clinical impact of pharmacogenetics on the treatment of epilepsy
- (2008) Wolfgang Löscher et al. EPILEPSIA
- Effect of CYP2C19 Genetic Polymorphisms on the Efficacy of Proton Pump Inhibitor-Based Triple Therapy forHelicobacter pyloriEradication: A Meta-Analysis
- (2008) Fujun Zhao et al. HELICOBACTER
- CYP2C19Genotype Is a Major Factor Contributing to the Highly Variable Pharmacokinetics of Voriconazole
- (2008) Johanna Weiss et al. JOURNAL OF CLINICAL PHARMACOLOGY
- CYP2C19 genotypes andHelicobacter pylorieradication
- (2008) Bor-Shyang Sheu et al. JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
- Cytochrome P-450 Polymorphisms and Response to Clopidogrel
- (2008) Jessica L. Mega et al. NEW ENGLAND JOURNAL OF MEDICINE
- The AmpliChip CYP450 test: cytochrome P450 2D6 genotype assessment and phenotype prediction
- (2008) M C Rebsamen et al. PHARMACOGENOMICS JOURNAL
- Role ofCYP2C9 andCYP2C19 polymorphisms in patients with atherosclerosis
- (2007) B. Ercan et al. CELL BIOCHEMISTRY AND FUNCTION
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started